Loading…

Differential Sensitivity of Mesencephalic Neurons to Inhibition of Phosphatase 2A

Disturbance in phosphorylation/dephosphorylation can trigger apoptosis. Little is known as to its effects on mesencephalic dopamine neurons, the major neurons lost in Parkinson's disease. In this study, okadaic acid (OKA), a phosphatase 1 and 2A inhibitor, with greater potency toward 2A, was to...

Full description

Saved in:
Bibliographic Details
Published in:The Journal of pharmacology and experimental therapeutics 2001-09, Vol.298 (3), p.925-933
Main Authors: Zeevalk, Gail D., Bernard, Laura P., Manzino, Lawrence, Sonsalla, Patricia K.
Format: Article
Language:English
Subjects:
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites
container_end_page 933
container_issue 3
container_start_page 925
container_title The Journal of pharmacology and experimental therapeutics
container_volume 298
creator Zeevalk, Gail D.
Bernard, Laura P.
Manzino, Lawrence
Sonsalla, Patricia K.
description Disturbance in phosphorylation/dephosphorylation can trigger apoptosis. Little is known as to its effects on mesencephalic dopamine neurons, the major neurons lost in Parkinson's disease. In this study, okadaic acid (OKA), a phosphatase 1 and 2A inhibitor, with greater potency toward 2A, was toxic to mesencephalic dopamine and γ-aminobutyric acid (GABA) neurons, however, dopamine neurons were 4-fold more sensitive. The EC50 for dopamine versus GABA toxicity was 1.5 versus 6.5 nM, respectively, and was consistent with an inhibition of phosphatase 2A. Dopamine neurons were also more sensitive to calyculin-A, a phosphatase inhibitor equipotent toward 1 and 2A. OKA-methyl-ester, which lacks phosphatase inhibitory activity, was without effect. DNA laddering typical of apoptosis was observed in cultures at a concentration that was specifically toxic to dopamine neurons (5 nM). In contrast to the sensitivity of mesencephalic neurons to phosphatase inhibition, inhibition of protein kinase activity with staurosporine or K252a showed little toxicity and protected neurons from OKA. Consistent with in vitro findings, infusion of 32 to 320 pmol of OKA into the left striatum of rats caused a dose-dependent loss of striatal dopamine without any loss of GABA 1 week following infusion. Acutely, OKA increased tyrosine hydroxylase activity, a phosphatase 2A substrate, and increased dopamine turnover. The above-mentioned findings demonstrate that dysregulation of phosphatase activity is detrimental to mesencephalic neurons, with dopamine neurons, in vitro and in vivo, being relatively more sensitive to phosphatase 2A inhibition. Disturbances in the phosphorylation control of proteins unique to dopamine neurons may contribute to their enhanced vulnerability to OKA exposure.
doi_str_mv 10.1016/S0022-3565(24)29458-1
format article
fullrecord <record><control><sourceid>pubmed_highw</sourceid><recordid>TN_cdi_pubmed_primary_11504786</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0022356524294581</els_id><sourcerecordid>11504786</sourcerecordid><originalsourceid>FETCH-LOGICAL-e294t-65927dfcb1fbc78e4fa4853b4ef12ac271ed23fdc7208a8fc718248326e4970f3</originalsourceid><addsrcrecordid>eNo90MtOwzAQBVALgWgpfAIoKwSLgJ-Js0JVeUrlpcLacpxxY5QmVZwW9e9xWmA1mzOjOxehU4KvCCbJ9QxjSmMmEnFB-SXNuJAx2UNDIiiJMcFsHw3_yQAdef-FMeE8YYdoQIjAPJXJEL3fOmuhhbpzuopmUHvXubXrNlFjo2fwUBtYlrpyJnqBVdvUPuqa6KkuXR5gU_fsrWx8MJ32ENHxMTqwuvJw8jtH6PP-7mPyGE9fH54m42kMIWwXJyKjaWFNTmxuUgncai4FyzlYQrWhKYGCMluYlGKppTUpkZRLRhPgWYotG6Gz3d3lKl9AoZatW-h2o_5-C-B8B0o3L79dCyqEbBfaNFUz3yiaScVURkWANzsIIe7aQau8cf3jRVgynSoapwhWfe1qW7vqO1WUq23tirAfMb1znw</addsrcrecordid><sourcetype>Index Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Differential Sensitivity of Mesencephalic Neurons to Inhibition of Phosphatase 2A</title><source>Freely Accessible Medical Journals</source><creator>Zeevalk, Gail D. ; Bernard, Laura P. ; Manzino, Lawrence ; Sonsalla, Patricia K.</creator><creatorcontrib>Zeevalk, Gail D. ; Bernard, Laura P. ; Manzino, Lawrence ; Sonsalla, Patricia K.</creatorcontrib><description>Disturbance in phosphorylation/dephosphorylation can trigger apoptosis. Little is known as to its effects on mesencephalic dopamine neurons, the major neurons lost in Parkinson's disease. In this study, okadaic acid (OKA), a phosphatase 1 and 2A inhibitor, with greater potency toward 2A, was toxic to mesencephalic dopamine and γ-aminobutyric acid (GABA) neurons, however, dopamine neurons were 4-fold more sensitive. The EC50 for dopamine versus GABA toxicity was 1.5 versus 6.5 nM, respectively, and was consistent with an inhibition of phosphatase 2A. Dopamine neurons were also more sensitive to calyculin-A, a phosphatase inhibitor equipotent toward 1 and 2A. OKA-methyl-ester, which lacks phosphatase inhibitory activity, was without effect. DNA laddering typical of apoptosis was observed in cultures at a concentration that was specifically toxic to dopamine neurons (5 nM). In contrast to the sensitivity of mesencephalic neurons to phosphatase inhibition, inhibition of protein kinase activity with staurosporine or K252a showed little toxicity and protected neurons from OKA. Consistent with in vitro findings, infusion of 32 to 320 pmol of OKA into the left striatum of rats caused a dose-dependent loss of striatal dopamine without any loss of GABA 1 week following infusion. Acutely, OKA increased tyrosine hydroxylase activity, a phosphatase 2A substrate, and increased dopamine turnover. The above-mentioned findings demonstrate that dysregulation of phosphatase activity is detrimental to mesencephalic neurons, with dopamine neurons, in vitro and in vivo, being relatively more sensitive to phosphatase 2A inhibition. Disturbances in the phosphorylation control of proteins unique to dopamine neurons may contribute to their enhanced vulnerability to OKA exposure.</description><identifier>ISSN: 0022-3565</identifier><identifier>EISSN: 1521-0103</identifier><identifier>DOI: 10.1016/S0022-3565(24)29458-1</identifier><identifier>PMID: 11504786</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Animals ; Cell Count ; Cells, Cultured ; DNA Fragmentation ; Dopamine - metabolism ; Enzyme Inhibitors - pharmacology ; gamma-Aminobutyric Acid - metabolism ; gamma-Aminobutyric Acid - physiology ; Immunohistochemistry ; Injections ; Male ; Mesencephalon - cytology ; Mesencephalon - drug effects ; Neostriatum - physiology ; Neurons - drug effects ; Okadaic Acid - administration &amp; dosage ; Okadaic Acid - pharmacology ; Phosphoprotein Phosphatases - antagonists &amp; inhibitors ; Phosphorylation ; Protein Phosphatase 1 ; Protein Phosphatase 2 ; Rats ; Rats, Sprague-Dawley ; Staurosporine - administration &amp; dosage ; Staurosporine - pharmacology ; Tyrosine 3-Monooxygenase - metabolism</subject><ispartof>The Journal of pharmacology and experimental therapeutics, 2001-09, Vol.298 (3), p.925-933</ispartof><rights>2001 American Society for Pharmacology and Experimental Therapeutics</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/11504786$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Zeevalk, Gail D.</creatorcontrib><creatorcontrib>Bernard, Laura P.</creatorcontrib><creatorcontrib>Manzino, Lawrence</creatorcontrib><creatorcontrib>Sonsalla, Patricia K.</creatorcontrib><title>Differential Sensitivity of Mesencephalic Neurons to Inhibition of Phosphatase 2A</title><title>The Journal of pharmacology and experimental therapeutics</title><addtitle>J Pharmacol Exp Ther</addtitle><description>Disturbance in phosphorylation/dephosphorylation can trigger apoptosis. Little is known as to its effects on mesencephalic dopamine neurons, the major neurons lost in Parkinson's disease. In this study, okadaic acid (OKA), a phosphatase 1 and 2A inhibitor, with greater potency toward 2A, was toxic to mesencephalic dopamine and γ-aminobutyric acid (GABA) neurons, however, dopamine neurons were 4-fold more sensitive. The EC50 for dopamine versus GABA toxicity was 1.5 versus 6.5 nM, respectively, and was consistent with an inhibition of phosphatase 2A. Dopamine neurons were also more sensitive to calyculin-A, a phosphatase inhibitor equipotent toward 1 and 2A. OKA-methyl-ester, which lacks phosphatase inhibitory activity, was without effect. DNA laddering typical of apoptosis was observed in cultures at a concentration that was specifically toxic to dopamine neurons (5 nM). In contrast to the sensitivity of mesencephalic neurons to phosphatase inhibition, inhibition of protein kinase activity with staurosporine or K252a showed little toxicity and protected neurons from OKA. Consistent with in vitro findings, infusion of 32 to 320 pmol of OKA into the left striatum of rats caused a dose-dependent loss of striatal dopamine without any loss of GABA 1 week following infusion. Acutely, OKA increased tyrosine hydroxylase activity, a phosphatase 2A substrate, and increased dopamine turnover. The above-mentioned findings demonstrate that dysregulation of phosphatase activity is detrimental to mesencephalic neurons, with dopamine neurons, in vitro and in vivo, being relatively more sensitive to phosphatase 2A inhibition. Disturbances in the phosphorylation control of proteins unique to dopamine neurons may contribute to their enhanced vulnerability to OKA exposure.</description><subject>Animals</subject><subject>Cell Count</subject><subject>Cells, Cultured</subject><subject>DNA Fragmentation</subject><subject>Dopamine - metabolism</subject><subject>Enzyme Inhibitors - pharmacology</subject><subject>gamma-Aminobutyric Acid - metabolism</subject><subject>gamma-Aminobutyric Acid - physiology</subject><subject>Immunohistochemistry</subject><subject>Injections</subject><subject>Male</subject><subject>Mesencephalon - cytology</subject><subject>Mesencephalon - drug effects</subject><subject>Neostriatum - physiology</subject><subject>Neurons - drug effects</subject><subject>Okadaic Acid - administration &amp; dosage</subject><subject>Okadaic Acid - pharmacology</subject><subject>Phosphoprotein Phosphatases - antagonists &amp; inhibitors</subject><subject>Phosphorylation</subject><subject>Protein Phosphatase 1</subject><subject>Protein Phosphatase 2</subject><subject>Rats</subject><subject>Rats, Sprague-Dawley</subject><subject>Staurosporine - administration &amp; dosage</subject><subject>Staurosporine - pharmacology</subject><subject>Tyrosine 3-Monooxygenase - metabolism</subject><issn>0022-3565</issn><issn>1521-0103</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2001</creationdate><recordtype>article</recordtype><recordid>eNo90MtOwzAQBVALgWgpfAIoKwSLgJ-Js0JVeUrlpcLacpxxY5QmVZwW9e9xWmA1mzOjOxehU4KvCCbJ9QxjSmMmEnFB-SXNuJAx2UNDIiiJMcFsHw3_yQAdef-FMeE8YYdoQIjAPJXJEL3fOmuhhbpzuopmUHvXubXrNlFjo2fwUBtYlrpyJnqBVdvUPuqa6KkuXR5gU_fsrWx8MJ32ENHxMTqwuvJw8jtH6PP-7mPyGE9fH54m42kMIWwXJyKjaWFNTmxuUgncai4FyzlYQrWhKYGCMluYlGKppTUpkZRLRhPgWYotG6Gz3d3lKl9AoZatW-h2o_5-C-B8B0o3L79dCyqEbBfaNFUz3yiaScVURkWANzsIIe7aQau8cf3jRVgynSoapwhWfe1qW7vqO1WUq23tirAfMb1znw</recordid><startdate>20010901</startdate><enddate>20010901</enddate><creator>Zeevalk, Gail D.</creator><creator>Bernard, Laura P.</creator><creator>Manzino, Lawrence</creator><creator>Sonsalla, Patricia K.</creator><general>Elsevier Inc</general><general>American Society for Pharmacology and Experimental Therapeutics</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope></search><sort><creationdate>20010901</creationdate><title>Differential Sensitivity of Mesencephalic Neurons to Inhibition of Phosphatase 2A</title><author>Zeevalk, Gail D. ; Bernard, Laura P. ; Manzino, Lawrence ; Sonsalla, Patricia K.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-e294t-65927dfcb1fbc78e4fa4853b4ef12ac271ed23fdc7208a8fc718248326e4970f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2001</creationdate><topic>Animals</topic><topic>Cell Count</topic><topic>Cells, Cultured</topic><topic>DNA Fragmentation</topic><topic>Dopamine - metabolism</topic><topic>Enzyme Inhibitors - pharmacology</topic><topic>gamma-Aminobutyric Acid - metabolism</topic><topic>gamma-Aminobutyric Acid - physiology</topic><topic>Immunohistochemistry</topic><topic>Injections</topic><topic>Male</topic><topic>Mesencephalon - cytology</topic><topic>Mesencephalon - drug effects</topic><topic>Neostriatum - physiology</topic><topic>Neurons - drug effects</topic><topic>Okadaic Acid - administration &amp; dosage</topic><topic>Okadaic Acid - pharmacology</topic><topic>Phosphoprotein Phosphatases - antagonists &amp; inhibitors</topic><topic>Phosphorylation</topic><topic>Protein Phosphatase 1</topic><topic>Protein Phosphatase 2</topic><topic>Rats</topic><topic>Rats, Sprague-Dawley</topic><topic>Staurosporine - administration &amp; dosage</topic><topic>Staurosporine - pharmacology</topic><topic>Tyrosine 3-Monooxygenase - metabolism</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Zeevalk, Gail D.</creatorcontrib><creatorcontrib>Bernard, Laura P.</creatorcontrib><creatorcontrib>Manzino, Lawrence</creatorcontrib><creatorcontrib>Sonsalla, Patricia K.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><jtitle>The Journal of pharmacology and experimental therapeutics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Zeevalk, Gail D.</au><au>Bernard, Laura P.</au><au>Manzino, Lawrence</au><au>Sonsalla, Patricia K.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Differential Sensitivity of Mesencephalic Neurons to Inhibition of Phosphatase 2A</atitle><jtitle>The Journal of pharmacology and experimental therapeutics</jtitle><addtitle>J Pharmacol Exp Ther</addtitle><date>2001-09-01</date><risdate>2001</risdate><volume>298</volume><issue>3</issue><spage>925</spage><epage>933</epage><pages>925-933</pages><issn>0022-3565</issn><eissn>1521-0103</eissn><abstract>Disturbance in phosphorylation/dephosphorylation can trigger apoptosis. Little is known as to its effects on mesencephalic dopamine neurons, the major neurons lost in Parkinson's disease. In this study, okadaic acid (OKA), a phosphatase 1 and 2A inhibitor, with greater potency toward 2A, was toxic to mesencephalic dopamine and γ-aminobutyric acid (GABA) neurons, however, dopamine neurons were 4-fold more sensitive. The EC50 for dopamine versus GABA toxicity was 1.5 versus 6.5 nM, respectively, and was consistent with an inhibition of phosphatase 2A. Dopamine neurons were also more sensitive to calyculin-A, a phosphatase inhibitor equipotent toward 1 and 2A. OKA-methyl-ester, which lacks phosphatase inhibitory activity, was without effect. DNA laddering typical of apoptosis was observed in cultures at a concentration that was specifically toxic to dopamine neurons (5 nM). In contrast to the sensitivity of mesencephalic neurons to phosphatase inhibition, inhibition of protein kinase activity with staurosporine or K252a showed little toxicity and protected neurons from OKA. Consistent with in vitro findings, infusion of 32 to 320 pmol of OKA into the left striatum of rats caused a dose-dependent loss of striatal dopamine without any loss of GABA 1 week following infusion. Acutely, OKA increased tyrosine hydroxylase activity, a phosphatase 2A substrate, and increased dopamine turnover. The above-mentioned findings demonstrate that dysregulation of phosphatase activity is detrimental to mesencephalic neurons, with dopamine neurons, in vitro and in vivo, being relatively more sensitive to phosphatase 2A inhibition. Disturbances in the phosphorylation control of proteins unique to dopamine neurons may contribute to their enhanced vulnerability to OKA exposure.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>11504786</pmid><doi>10.1016/S0022-3565(24)29458-1</doi><tpages>9</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0022-3565
ispartof The Journal of pharmacology and experimental therapeutics, 2001-09, Vol.298 (3), p.925-933
issn 0022-3565
1521-0103
language eng
recordid cdi_pubmed_primary_11504786
source Freely Accessible Medical Journals
subjects Animals
Cell Count
Cells, Cultured
DNA Fragmentation
Dopamine - metabolism
Enzyme Inhibitors - pharmacology
gamma-Aminobutyric Acid - metabolism
gamma-Aminobutyric Acid - physiology
Immunohistochemistry
Injections
Male
Mesencephalon - cytology
Mesencephalon - drug effects
Neostriatum - physiology
Neurons - drug effects
Okadaic Acid - administration & dosage
Okadaic Acid - pharmacology
Phosphoprotein Phosphatases - antagonists & inhibitors
Phosphorylation
Protein Phosphatase 1
Protein Phosphatase 2
Rats
Rats, Sprague-Dawley
Staurosporine - administration & dosage
Staurosporine - pharmacology
Tyrosine 3-Monooxygenase - metabolism
title Differential Sensitivity of Mesencephalic Neurons to Inhibition of Phosphatase 2A
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-02T22%3A49%3A11IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed_highw&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Differential%20Sensitivity%20of%20Mesencephalic%20Neurons%20to%20Inhibition%20of%20Phosphatase%202A&rft.jtitle=The%20Journal%20of%20pharmacology%20and%20experimental%20therapeutics&rft.au=Zeevalk,%20Gail%20D.&rft.date=2001-09-01&rft.volume=298&rft.issue=3&rft.spage=925&rft.epage=933&rft.pages=925-933&rft.issn=0022-3565&rft.eissn=1521-0103&rft_id=info:doi/10.1016/S0022-3565(24)29458-1&rft_dat=%3Cpubmed_highw%3E11504786%3C/pubmed_highw%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-e294t-65927dfcb1fbc78e4fa4853b4ef12ac271ed23fdc7208a8fc718248326e4970f3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_id=info:pmid/11504786&rfr_iscdi=true